PATENT CLAIM ANALYSIS

Application Number: 15976225
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "017700"]

Abstract:
The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Claim (Index 38):
A method of measuring the activity of a biglycan polypeptide, comprising administering the biglycan polypeptide to a test cell that expresses utrophin and comparing an amount of membrane-associated utrophin in the test cell with an amount of membrane-associated utrophin in a control cell that did not receive biglycan polypeptide, wherein an increased amount of membrane-associated utrophin in the test cell is indicative of biglycan activity.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.55738
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13109558', '13996951', '12786294', '10486678', '10868247']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8434890197837983
- 35 USC 102 Novelty (BERT): 0.6561618506503328
- Combined Prediction Score: 0.8247563028704518
- Mean Citation Score: 674.5547960000001
- Max Citation Score: 775.4225
- Similarity Product: 582.7021007397769

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test